TGA guidelines for sterility testing of
therapeutic goods
September 2006
Therapeutic Goods Administration
About the Therapeutic Goods Administration (TGA)
 The TGA is a division of the Australian Government Department of Health and Ageing, and is
responsible for regulating medicines and medical devices.
 TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management
approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards
of quality, safety and efficacy (performance), when necessary.
 The work of the TGA is based on applying scientific and clinical expertise to decision-making, to
ensure that the benefits to consumers outweigh any risks associated with the use of medicines
and medical devices.
 The TGA relies on the public, healthcare professionals and industry to report problems with
medicines or medical devices. TGA investigates reports received by it to determine any
necessary regulatory action.
 To report a problem with a medicine or medical device, please see the information on the TGA
website.
Copyright
© Commonwealth of Australia 2006
This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be
reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries
concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration,
Attorney General’s Department, National Circuit, Barton ACT 2600 or posted at http://www.ag.gov.au/cca
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page i
Therapeutic Goods Administration
Contents
1.
INTRODUCTION
5
Regulatory aspects _________________________________________________________ 5
Rationale ______________________________________________________________________ 5
2.
SAMPLING OF LOTS
7
3.
PRECAUTIONS AGAINST MICROBIAL CONTAMINATION 10
4.
TEST METHODS
11
General Methodology ____________________________________________________ 11
Test method validation _____________________________________________________________ 11
Method of Membrane Filtration _________________________________________ 12
PROCEDURES _______________________________________________________________________ 12
Aqueous solutions and suspensions which may be filtered directly
12
Aqueous solutions and suspensions which must be diluted or
treated prior to filtration
14
Soluble or dispersible solids
14
Ointments and oily preparations
14
INITIAL VALIDATION OF THE TEST METHOD - TESTING FOR RESIDUAL
ANTIMICROBIAL ACTIVITY ________________________________________________________ 16
Method of Direct Transfer _______________________________________________ 16
PROCEDURES _______________________________________________________________________ 16
Liquids and soluble or dispersible solids
Solid articles
Ointments and oily preparations
16
17
17
INITIAL VALIDATION OF THE TEST METHOD - TESTING FOR
ANTIMICROBIAL ACTIVITY ________________________________________________________ 18
Negative Product Control Tests ________________________________________ 18
Incubation and Examination of Sterility Tests _______________________ 19
Monitoring the efficacy of test media at the end of the incubation
period (stasis test) ________________________________________________________ 20
Interpretation of the Test Results ______________________________________ 20
5.
RECORDS
22
6.
MEDIA FOR USE IN STERILITY TESTING
23
Composition _______________________________________________________________ 23
Method of Preparation ___________________________________________________ 23
Tests on the Media ________________________________________________________ 23
Shelf-life ____________________________________________________________________ 24
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 3 of 36
Therapeutic Goods Administration
7. DILUENTS, SOLVENTS AND WASH SOLUTIONS FOR USE
IN STERILITY TESTING
25
Composition _______________________________________________________________ 25
Method of Preparation ___________________________________________________ 25
Tests on Diluents, Solvents and Wash Solutions___________________ 25
Shelf-life ____________________________________________________________________ 25
ANNEX I. GUIDANCE ON OBTAINING SMALL NUMBERS OF
VEGETATIVE ORGANISMS AND SPORES
26
ANNEX II.
COMPOSITION AND PREPARATION OF MEDIA 30
ANNEX III.
COMPOSITION AND PREPARATION OF DILUENTS32
ANNEX IV.
STERILITY TEST ENVIRONMENT
TGA guidelines for sterility testing of therapeutic goods
September 2006
33
Page 4 of 36
Therapeutic Goods Administration
1.
INTRODUCTION
100.
Relevant section of the BP/Ph Eur: ‘Guidelines for Using the Test for Sterility’
Regulatory aspects
101.
The TGA Guidelines on Sterility Testing of Therapeutic Goods provide guidance for
sterility testing of sterile therapeutic drugs and devices supplied in Australia for human use.
They are intended for use by manufacturers and the Official Analysts of the Therapeutic Goods
Administration (TGA) Laboratories, and as guidance for referee testing when results are in
dispute. Some sections therefore include information relating to referee testing.
102.
It should be noted that these Guidelines are not mandatory for industry. The official
(legal) requirements for sterility tests in Australia are currently those specified in the most
recently gazetted British Pharmacopoeia (BP), which are aligned with the European
Pharmacopoeia (Ph Eur). Therapeutic Goods Order Number 11 Standard for Sterile
Therapeutic Goods was revoked on the date of adoption of the BP 1998. The BP, Ph Eur and
US Pharmacopoeia (USP) sterility test methods became harmonised with the publication of the
BP 2004, Ph Eur 5.1 and USP 28 editions and as such all are considered to be acceptable by
the TGA.
103.
These Guidelines are based on the superseded document Australian Code of Good
Manufacturing Practice for Therapeutic Goods - Medicinal Products - Appendix C Guidelines on
Tests for Sterility, 1990 (Appendix C). They also incorporate the BP/Ph Eur requirements with
additional elements from the Pharmaceutical Inspection Convention/Pharmaceutical Inspection
Co-operation Scheme (PIC/S) Recommendations on Sterility Testing, the USP and the
combined experience of the TGA Laboratories, manufacturers and contract testing laboratories.
104.
Sampling schedules and specific guidance for testing of medical devices are provided
because these are not included in the BP/Ph Eur. Sampling schedules are based on those of
the USP 28 effective January 2005.
105.
Where the Guidelines describe particular procedural steps and media, it should be
understood that other procedures and other media may be equally satisfactory,
provided that their use can be validated. However, when the results of a sterility test
performed by the TGA Official Analyst are challenged, the combined procedures of the
BP/Ph Eur test and this document must be followed.
106.
Where reference is made to the ‘competent authority’ throughout this document, the
TGA fulfils this role in Australia.
Rationale
107.
Success in detecting microbial contamination of goods is dependent inter alia upon
statistical considerations. Generally, the odds are against detecting a low level of contamination,
ie, when relatively few organisms contaminate a small proportion of items. Detection of
contamination with absolute certainty would necessitate the examination of all items of the
batch using media capable of supporting the growth of all possible contaminants.
108.
In the BP/Ph Eur sterility test prior to 1998, when contamination was found in a primary
test, a repeat test was permitted as a check against the possibility that the contamination was
introduced by the operator and was not a contamination of the material tested. Repeat testing
reduces the efficiency of testing because the probability of accepting a contaminated batch is
thereby increased.
109.
The probability of including contaminated items in two successive samples taken from a
given batch is the product of the probabilities of a contaminated item being included in each of
the single samples. For example, with a sample size of 10 and a contamination rate of 5% the
probability of including a contaminated item is 0.4 (see Table 1).
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 5 of 36
Therapeutic Goods Administration
110.
If the test is repeated with another sample size of 10 units the probability of including a
contaminated item is again 0.4. However, the probability of both tests being positive is 0.4 x 0.4
= 0.16 which is lower than the probability of the first test, and hence in 84 of 100 such tests the
batch will be accepted as sterile.
TABLE 1: PROBABILITIES OF DETECTING A CONTAMINATED LOT IN A SINGLE TEST
Percentage of Items
contaminated
0.1
1.0
2.0
5.0
Sample size 10
0.01
0.09
0.18
0.40
Sample size 20
0.02
0.18
0.33
0.65
Sample size 50
0.05
0.39
0.64
0.92
Sample size 100
0.09
0.63
0.87
0.99
111.
A repeat test is now permitted only if it can be clearly demonstrated that the test was
invalid for causes unrelated to the product being examined (see clauses 492-496).
112.
Sterility cannot be guaranteed by the quality control laboratory. It must be built into the
product during processing. Experience in many countries over the years has confirmed that
greater reliance must be placed on appropriate techniques and procedures throughout the
manufacture of the product (including in-process sterility testing at various stages) rather than
simply depending on sterility tests made on a number of samples of the final batch as the sole
criterion of sterility.
113.
Permission to delete the sterility test from batch release specifications may be granted
by the competent authority where manufacturing standards are of a high order and the product
is terminally sterilised in its final container.
114.
In all other cases, sterility testing is necessary to detect contamination arising from
technical malfunction, human error or mix-up between sterilised and non-sterilised goods. It
must be performed as part of batch release specifications for product that is not terminally
sterilised in the final container. It is also the only analytical method available for finished product
testing by the competent authority.
115.
It is important to realise that background contamination as detected by negative controls
can obscure low levels of product contamination and for this reason every effort should be
made to ensure that background contamination is kept as low as possible. Statistics compiled
by the TGA Laboratories show that skilled operators working under the prescribed conditions
can achieve a level as low as one contamination in five thousand control inoculations (0.02%).
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 6 of 36
Therapeutic Goods Administration
2.
SAMPLING OF LOTS
200.
Relevant sections of the BP/Ph Eur: ‘Application of the test to parenteral
preparations, ophthalmic and other non-injectable preparations required to comply with
the test for sterility’; ‘Guidance to manufacturers’; Tables 2.6.1.-2 and 2.6.1.-3.
201.
The sampling schedules in Tables 2 and 3 set out the minimum number of items to be
sampled from each batch (lot) and the minimum quantity to be tested from each container,
unless otherwise justified and authorised. The batch size and conditions of manufacture should
be considered when planning a sampling regimen and larger numbers and quantities may be
appropriate. It is assumed that the product has been manufactured under conditions designed
to exclude contamination.
202.
For the purposes of these Guidelines a batch of product is defined as a homogeneous
collection of sealed containers prepared in such a manner that the risk of contamination is the
same for each of the units of the batch. Where a batch is sterilised as a series of lots or subbatches, each of which is subjected to a separate sterilising cycle or is subjected in processing
to different treatment which may affect its sterility eg different freeze-drying cycles, each lot
should be tested for sterility.
203.
Any samples used for a sterility retest should reflect the original samples in terms of
sampling locations or process times.
204.
For aseptically prepared products, the samples should be taken at regular intervals
during the filling operations in such a way that every filling point is represented by an
approximately equivalent number of samples. Further, the first and last items dispensed at each
filling point and the first item filled after any machine break-down or change, any non-validated
intervention or interruption, should be included amongst the samples. Items selected as
samples need not be discarded if they are under-filled provided they contain sufficient volume of
product for the test. In the event of contamination being detected it is useful if the source and
place in the filling run of samples can be identified.
205.
For terminally sterilised products the samples should be made up from units drawn from
various sites throughout the steriliser load. Some of the units should be taken from that place in
the load known to be least accessible to the sterilising agent. Samples may be taken
representatively from across each load, if the conditions for filling the containers were such as
to satisfy the conditions for aseptically filled containers or the design of the equipment, the
specification of the sterilising cycles and the validation data for each class of product are
acceptable to the competent authority.
206.
The minimum number of items or quantity to be tested may be inappropriate for some
products and a smaller sample may be tested with the approval of the competent authority.
207.
The testing of products which are of high intrinsic value or which are intended for use in
clinical trials and which are dispensed in small volumes or produced in small lots of less than 20
containers, may be combined with the filling procedure using the following method:

a sterile membrane filter is incorporated in the filling line;

the containers are filled and a number of containers are sampled, the number and manner
of selection being as specified in clause 204 and Table 2;

the sample containers are swirled so as to ensure that the product contacts the entire
internal surface of the container, and then, using aseptic procedures, the containers are
opened and the contents are emptied back into the reservoir for the filling line;

the product is then refilled into fresh containers;

the in-line membrane filter is removed and tested for sterility by dividing it into two
approximately equal portions and testing one portion in Fluid Thioglycollate Medium
(Medium 1) and the other in Soybean-Casein Digest Medium (Medium 2) (see clauses 475479).
208.
Where the goods to be tested are intended for laboratory use only, the test for sterility
may be performed on smaller samples than those indicated above, where rational
considerations preclude such large-scale tests.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 7 of 36
Therapeutic Goods Administration
209.
When the test method is membrane filtration, whenever possible, the whole contents of
the container should be tested, but not less than the quantities indicated in Table 3.
TABLE 2: SAMPLING SCHEDULE - MINIMUM NUMBER OF ITEMS TO BE TESTED FROM
EACH BATCH1
Type of product
Number of items in the batch
Minimum number of items
to be tested for each
medium2
Injectable pharmaceuticals
Injectable medical devices
Ophthalmic and other noninjectable pharmaceuticals in
single-dose containers
Ophthalmic medical devices in
single-dose containers
Not more than 100
10% of batch or 4
containers, whichever is the
greater
101-500
10 containers
More than 500
2% of batch or 20
containers, whichever is the
lesser
Not more than 200
5% of batch or 2 containers,
whichever is the greater
More than 200
10 containers
Not more than 4
Each container
5-50
20% of batch or 4
containers, whichever is the
greater
More than 50
2% of batch or 10
containers, whichever is the
greater
Less than 5g
20 containers
Greater than or equal to 5g
6 containers
Not more than 100
10% of batch or 4 units,
whichever is the greater
101-500
10 units
More than 500
2% of batch or 20 units,
whichever is the lesser
Ophthalmic and other noninjectable pharmaceuticals and
medical devices not in singledose containers
Bulk solid products
Pharmacy bulk packages of
antibiotics
Solid medical devices
NOTES
1.
2.
This Table incorporates Table 2.6.1-3 (BP and Ph Eur) and Table 3 (USP).
If the contents of one container are sufficient to inoculate the two media, this column
gives the number of containers needed for both the media together.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 8 of 36
Therapeutic Goods Administration
TABLE 3: MINIMUM QUANTITY OF PRODUCT TO BE TESTED FROM EACH CONTAINER
IN THE SAMPLE1
Type of product
Quantity of product in unit
container
Minimum
quantity/proportion to be
used for each medium from
each container2
Liquids
Less than 1 mL
The whole contents
1 - 40 mL
Half the contents but not less
than 1 mL
41 - 100 mL
20 mL
Greater than 100 mL
10% of the contents but not
less than 20 mL
Antibiotic liquids
N/A
1 mL
Other preparations soluble in
water or isopropyl myristate
N/A
The whole contents to provide
not less than 200 mg
Insoluble preparations, creams
and ointments to be suspended
or emulsified
N/A
The whole contents to provide
not less than 200 mg
Solids
Less than 50 mg
The whole contents
50 - 299 mg
Half the contents but not less
than 50 mg
300 mg to 5 g
150 mg
Greater than 5 g
500 mg
One or more dressings
100mg
One or more devices
One whole device3,
cut/disassembled if necessary
Solid medical devices
NOTES
1.
2.
3.
This Table incorporates Table 2.6.1-2 (BP and Ph Eur) and Table 2 (USP).
Unless otherwise justified and authorised
Refer also to clauses 452 - 455.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 9 of 36
Therapeutic Goods Administration
3. PRECAUTIONS AGAINST MICROBIAL
CONTAMINATION
300.
Relevant section of the BP/Ph Eur: ‘Precautions against microbial contamination’
301.
Tests for sterility are to be carried out by trained personnel using techniques and
equipment which minimise the risks of accidental microbial contamination of the tests and of the
testing environment.
302.
Tests for sterility should be conducted in a clean-room environment that is equivalent to
the standard of clean-room required for the aseptic manufacture of pharmaceutical products.
Additional guidance is given in Annex IV.
303.
Personnel occupying the aseptic testing area during sterility testing or associated
aseptic manipulations should wear sterilised overgarments. The use of sanitised garments may
be acceptable under certain conditions (see Annex IV).
304.
All equipment, vessels and materials with which the sterile test media or the goods
under test may come into contact in the course of the testing should be sterilised prior to use.
Preferred methods are heating in an autoclave so that all surfaces are held at a temperature of
121°C and exposed to saturated steam for at least 15 minutes, or by heating to, and holding for
at least 2 hours at a temperature of 160°C in a hot air oven, or by exposure to a minimum
absorbed radiation dose of 25 kGy.
305.
All substances added to the goods tested, and all substances added to sterile media or
introduced into sterile membrane filtration units (other than the preparations under test) should
be sterilised prior to use by heat. If this reduces the effectiveness of the test the most effective
alternative method should be used.
306.
Prior to sterilisation, all vessels, substances or outer clothing to be used for the
performance of tests for sterility, or introduced into the testing area, should be appropriately
packaged or closed, so as to prevent access of micro-organisms. Each package or item
being sterilised should bear a visual indicator appropriate to the method of sterilisation to
indicate that it has been processed but the appropriate change in the appearance of the
indicator should not be taken as a guarantee of the sterility of the contents. Each package
or item should be dated with the date of sterilisation to assist in correct stock rotation.
307.
The outer surfaces of all packages of equipment, vessels, etc., which are introduced
into the aseptic testing environment (including vessels of media and packages or containers
of goods to be tested) should be free of contamination immediately prior to their introduction
into the aseptic environment: they should be sterilised or disinfected by an appropriate
method which does not prejudice the viability of micro-organisms which may be present in
the preparations to be tested. A pass-through hatch (or transfer box) is considered part of
the testing environment. If the packages are double-wrapped and sterilised the outer
wrapping should be removed just prior to the introduction of the package into the testing
environment.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 10 of 36
Therapeutic Goods Administration
4.
TEST METHODS
400.
Relevant sections of the BP/Ph Eur: ‘Test for sterility of the product to be
examined’; ‘Validation test’; ‘Observation and interpretation of results’; ‘Application of
the test to parenteral preparations, ophthalmic and other non-injectable preparations
required to comply with the test for sterility’
General methodology
401.
Tests for sterility are carried out by the method of Membrane Filtration, by the method of
Direct Transfer or by Addition of Concentrated Medium to the product. The method of
Membrane Filtration should be used as the method of choice wherever feasible.
402.
Fluid Thioglycollate Medium (Medium 1) and Soybean-Casein Digest Medium (Medium
2) are the media generally used for tests for sterility (see Section 6). Alternative media types
may be appropriate where the nature of the product or method of manufacture can result in the
presence of fastidious organisms (eg vaccines, blood products). Validation studies should
indicate that alternative media are capable of supporting the growth of a wide range of microorganisms in the presence of the product.
403.
Where the preparation to be tested has antimicrobial effects, these effects may be
reduced or neutralised by adding an appropriate substance to the specified test media, to
diluents or solvents, or to the preparation prior to testing. Media so modified should be
subjected to the tests described for unmodified media in clauses 608-616 and should only be
used in tests for sterility if found to comply.
404.
Containers of Medium 1 are incubated at 30 - 35°C and Medium 2 at 20 - 25°C.
Test method validation
405.
Before tests for sterility for any product are initially carried out, it is necessary to
demonstrate the validity of the test method used by recovery of a small number of microorganisms in the presence of the product (see Annex I Guidance on Obtaining Small Numbers
of Vegetative Organisms and Spores). It is preferable to add these challenge organisms directly
to the product prior to membrane filtration or direct inoculation; where this is not practicable due
to inhibition or irreversible binding by the product, the challenge organisms should be added to
the last rinse solution if the membrane filtration method is used, or directly to the media
containing the product if the direct method is used.
406.
Validation should mimic the test proper in every detail, such as in the volumes of media
used, quantities and dilutions of product and diluents: the approach depends on the method of
test and details are given in each section. It may be performed concurrently with the actual test
for sterility but should be confirmed as successful before the results of the sterility test are
interpreted.
407.
Validation is to be performed when the test for sterility has to be carried out on
reformulated or new product, or whenever there is a change in the experimental
conditions of the test. It is good practice to revalidate test methodology every 12 months
although this is not a pharmacopoeial requirement and the frequency can be varied
depending on frequency of manufacture, the nature and ingredients of the product and
the frequency of stasis testing.
408.
If a test method cannot be satisfactorily validated the regulatory authority should be
notified.
409.
All validation procedures should be carried out by personnel who are responsible for the
routine testing of the product and should be done for each facility manufacturing that
product.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 11 of 36
Therapeutic Goods Administration
Method of membrane filtration
Procedures
410.
The filter should be a membrane filter disc of cellulose esters or other suitable plastics,
having a nominal average pore diameter not exceeding 0.45µm. The membrane should be held
firmly in a filtration unit which consists of a supporting base for the membrane, a receptacle for
the fluid to be tested, a collecting reservoir for the filtered fluid, and the necessary tubes or
connections. The apparatus is so designed that the solution to be filtered can be introduced and
filtered under aseptic conditions. It permits the aseptic removal of the membrane for transfer to
medium or it is suitable for carrying out the incubation after adding the medium to the apparatus
itself.
411.
Where the product has antimicrobial activity, the use of hydrophobic edged membranes
is recommended so as to facilitate washing, unless self-contained canister systems are
employed.
412.
Cellulose nitrate filters are recommended for aqueous, oily and weakly alcoholic
solutions and cellulose acetate filters for strongly alcoholic solutions.
413.
The entire unit should be sterilised by appropriate means with the membrane filter and
sterile airways in place. The method of sterilisation should not be deleterious to the membrane,
eg, weaken it or change the nominal average pore diameter. The sterile airways should provide
free access to the sterilising agent. After sterilisation, the apparatus should be free of leaks to
the atmosphere except through the sterile airways.
414.
The filter should be pre-wetted with diluent or solvent before filtration to minimise the
retention of sample, particularly where small volumes and antibiotics are tested. A visual check
of the integrity of the filter membrane should be carried out after filtration has been completed
and the test shall be invalid if defects are apparent.
415.
The specific diluents referred to in Table 4 and in the sections below are not obligatory
and alternatives may be used provided they are compatible with the membrane and do not have
antimicrobial activity as demonstrated by validation studies. It is assumed that membranes of
approximately 50 mm diameter are used in the methods described below. If filters of a different
diameter are used the volumes of diluents and wash solutions should be adjusted appropriately.
The total volume washed through one single membrane should not exceed 1000 mL unless
otherwise justified and authorised.
Aqueous solutions and suspensions which may be filtered directly
416.
The prescribed volumes (Tables 2 and 3) of aqueous solutions and suspensions which
can be filtered without prior treatment or dilution are transferred from the containers of the
product to a sterile filtration unit. Filtration is then carried out with the aid of suction or pressure.
417.
Without delay the filter membrane(s) should be washed not less than three times with
the diluent specified in Table 4 or an equivalent. Throughout the operation the membrane
should remain covered with liquid. If the original preparation contains a preservative or has
inherent antimicrobial activity, additional washes may be needed and/or the diluent may include
an antimicrobial inactivator. The volume of diluent must be equal to that used during validation.
418.
After filtration and washing, aseptically divide the filter into two parts of approximately
equal surface area and transfer one part to Medium 1 and the other part to Medium 2.
419.
The volume of Medium 1 should be such that the air space above the medium in the
container is minimised. The volume of Medium 2 should be such that sufficient air space is left
above the medium to provide conditions that permit the growth of obligate aerobes. This
condition applies irrespective of the filtration system used.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 12 of 36
Therapeutic Goods Administration
TABLE 4: SAMPLE TREATMENTS, SOLVENTS AND DILUENTS SUGGESTED FOR USE IN
STERILITY TESTS USING THE METHOD OF MEMBRANE FILTRATION1
Class of Sample
Treatment before filtration
(solution or dilution)3
Diluent for washing after
filtration3
Aqueous
solutions
Containing
lecithin
-
Diluent 2
Others
-
Diluent 1 or 2
With
ingredient
containing
beta-lactam
ring
Water soluble
substances
Water
insoluble
substances
(in solid form
or as aqueous
suspension)
Ointments
and oily
preparations
1.
2.
3.
Diluent 3 (one or more of the
washes)
Containing
lecithin
Dissolve in sterile water or
suitable solvent
Diluent 2
Others
Dissolve in sterile water or
suitable solvent
Diluent 1 or 2
With
ingredient
containing
beta-lactam
ring
Dissolve in sterile water or
suitable solvent or Diluent 3
Diluent 3 (one or more of the
washes)
Containing
lecithin
Suitable solvent
Diluent 2
Not containing
lecithin
Suitable solvent
Diluent 1 or 2
Containing a
beta-lactam
antibiotic
Diluent 3 or other solvent
containing penicillinase
Diluent 3
Dissolve in suitable solvent2
Diluent 2
In every case an equally or more effective diluent may be substituted for that suggested
in the table.
In some cases it may be necessary to use a mixture of solvents or several different
solvents in succession. Where the sample contains an antibiotic with a beta-lactam ring
it may be necessary to add penicillinase to one of the solvents or to the solvent mixture.
Refer to Annex III for composition and preparation of diluents.
420.
If test apparatus is used in which medium is added to the apparatus and the membrane
incubated in situ, the sample should be divided between two units or multiples thereof. Add
Medium 1 to one of the units and Medium 2 to the other unit.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 13 of 36
Therapeutic Goods Administration
421.
The minimum test is one in which a single membrane is divided into two parts and one
part is inoculated into Medium 1 and one part into Medium 2. The number of containers tested
may be increased to increase the statistical information provided by a test. If the full sample
cannot be passed through a single membrane because of filtration difficulties or unacceptable
levels of residual antimicrobial substance(s) in the filter membrane, the sample may be divided
into portions and each filtered separately. However, the transfer of membranes or parts of
membranes into the two media should not differ from the above proportions. Incubate test
vessels of Medium 1 at 30 - 35°C and the vessels of Medium 2 at 20 - 25°C.
Aqueous solutions and suspensions which must be diluted or treated prior to filtration
422.
Where aqueous solutions or suspensions must be diluted or treated prior to filtration
they should be diluted with diluents specified in Table 4 or a suitable alternative sterile diluent or
solvent and should be filtered, washed or otherwise treated as for those which may be filtered
directly.
423.
‘Suitable alternative’ is any other sterilised diluent in which the suspended substance is
soluble or which enables the substance to pass through the filter. Such alternative diluents
should not exhibit antimicrobial activity as demonstrated by validation studies.
424.
421.
The diluted or treated preparation should be filtered as described above in clauses 416-
Soluble or dispersible solids
425.
Prior to filtration, the quantity of a solid to be tested (see Tables 2 and 3), is transferred
from each container to one or more vessels to be pooled, dissolved or otherwise treated as
permitted by this method. This should be done in one or more vessels containing the suitable
solvent.
426.
In the case of solids in final dosage form, measured volumes of the suitable solvent
may be added directly to the final containers, and the test sample may then be withdrawn in the
form of a solution or a suspension.
427.
Appropriate diluents for use in these operations are listed in Table 4. A ‘suitable solvent’
for dissolving a water-insoluble solid is a solvent or a liquid that facilitates dissolution of the solid
and its passage through the filters. It should be sterile and should not exhibit antimicrobial
activity or change the nominal pore diameter of the filter membrane in the conditions of the test
as demonstrated by validation studies.
428.
The resulting preparation should be filtered as described above in clauses 416-421.
Ointments and oily preparations
429.
Oils and oily solutions of sufficiently low viscosity may be filtered without dilution
through a dry membrane.
430.
Viscous oils may be diluted as necessary with a suitable sterile diluent such as
isopropyl myristate shown not to have antimicrobial activity in the conditions of the test.
431.
Allow the oil to penetrate the membrane by its own weight, then filter, applying the
pressure or suction gradually. Wash the membrane not less than three times by filtering through
it about 100 mL of a suitable sterile solution such as Diluent 2.
432.
Ointments in a fatty base and emulsions of the water-in-oil type may be diluted to 1 per
cent in isopropyl myristate at a temperature of 40°C, but not more than 44°C. As rapidly as
possible the preparation should be filtered and the membranes washed without delay, as
described above for oils and oily solutions.
433.
The resulting preparation and filters should be cultured as described above in clauses
418-421.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 14 of 36
Therapeutic Goods Administration
Table 5:
Micro-organisms for use in growth promotion, validation and stasis tests 1
Micro-organism
Species
Incubation Conditions
Suitable strain
Type: anaerobic bacteria
Clostridium sporogenes
Maximum duration
30 – 35
3 days for growth
promotion.
ATCC 19404
CIP 79.3
NCTC 532
ATCC 11437
5 days for validation and
stasis.
30 – 35
Type: aerobic bacteria
Staphylococcus aureus
Temperature (°C)
ATCC 6538
CIP 4.83
NCTC 10788
NCIMB 9518
Pseudomonas
aeruginosa
ATCC 9027
NCIMB 8626
CIP 82.118
Bacillus subtilis
ATCC 6633
CIP 52.62
NCIMB 8054
5 days for validation and
stasis.
20 – 25
20 – 25
Type: fungi
Candida albicans
ATCC 10231
IP 48.72
NCPF 3179
Aspergillus niger
ATCC 16404
IP 1431.83
IMI 149007
3 days for growth
promotion.
5 days
NOTE:
1.
This Table incorporates Table 2.6.1.-1 (BP/Ph Eur) and Table 1 (USP).
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 15 of 36
Therapeutic Goods Administration
Initial validation of the test method - testing for residual antimicrobial
activity
434
To validate the test method, carry out the test procedures as described in the relevant
section above, up to the final wash procedure. To the final wash add an inoculum of not more
than 100 viable cells of each of the specified aerobic bacteria, anaerobic bacteria and fungi..
(For guidance on preparation of inocula, see Annex I Guidance on Obtaining Small Numbers of
Vegetative Organisms and Spores).
435
Add Clostridium sporogenes ATCC 19404, Staphylococcus aureus ATCC 6538 and
Pseudomonas aeruginosa ATCC 9027 to Medium 1 and Candida albicans ATCC 10231,
Bacillus subtilis ATCC 6633 and Aspergillus niger ATCC 16404 to Medium 2. Other appropriate
strains of challenge organisms are listed in Table 5..
436
After the final wash with the added micro-organisms has been passed through the filter,
incubate one filter disc in Medium 1 at 30 - 35°C and one in Medium 2 at 20 - 25°C.
437
If different culture conditions are to be used in the test for justified reasons, these must
be validated using challenge organisms appropriate for the conditions.
438.
Periodically, strains of micro-organisms collected from the manufacturing environment
should be used as challenge organisms.
439.
Growth of each of the added micro-organisms should be apparent within 48 hours. If
conspicuous growth does not occur within 5 days for each bacteria and fungi the test procedure
is not valid and must be modified (e.g. by using additional washes, using antagonists to the
antimicrobial agent or other procedure) until conspicuous growth does occur when tests as
above are carried out.
440.
If the membrane is found to be free of such antimicrobial activity when first tested or
after modification of procedures, application of the test to every sample is not necessary. (See
also clause 407).
Method of direct transfer
Procedures
Liquids and soluble or dispersible solids
441.
Transfer the quantity of the preparation to be examined as indicated in Table 3 directly
into Medium 1 and Medium 2. Approximately equal quantities of the preparation should
be added to each vessel of medium. Incubate the test vessels of Medium 1 at 30 - 35°C
and the vessels of Medium 2 at 20 - 25°C.
442.
The volume of Medium 1 should be such that the air space above the medium in the
container is minimised. The volume of Medium 2 should be such that sufficient air space is left
above the medium to provide conditions that permit the growth of obligate aerobes.
443
Unless otherwise prescribed, in no case should the volume of material under test be
greater than 10% of the volume of the medium alone, ie, 90% medium and 10% product.
444.
In the case of soluble or dispersible solids, a measured volume of Purified Water, or a
suitable sterilised diluent or solvent which does not manifest antimicrobial activity as
demonstrated by validation studies, should be added to each container of the solid. After the
contents have been dissolved or dispersed, the specified quantity of the product should then be
added in the form of a solution or suspension to the test media. Alternatively, the solid material
may be transferred directly to the test media.
445.
If a large volume of product is to be tested it may be preferable to use concentrated
media, prepared so as to take the subsequent dilution into account. Where appropriate the
concentrated medium may be added directly to the product in its container.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 16 of 36
Therapeutic Goods Administration
446.
Any additional diluents, solvents or procedures for carrying out the test should be
validated.
Solid articles
447.
Wherever possible solid articles such as devices should be tested by immersion in or
filling with culture media.
448.
Aseptically dismantle all articles as completely as possible. Articles such as tubing may
need to be cut. Other articles may need to be broken into smaller parts to allow access of
medium to all surfaces of the article.
449.
Immerse all parts of each article in sufficient medium contained in one vessel to
completely cover all parts. The volume of Medium 1 should be such that the air space above the
medium in the container is minimised. The volume of Medium 2 should be such that sufficient
air space is left above the medium to provide conditions that permit the growth of obligate
aerobes.
450.
Place half the articles into Medium 1 and the remaining half into Medium 2. Incubate the
test vessels of Medium 1 at 30 - 35°C and the vessels of Medium 2 at 20 - 25°C.
451.
Where the product is a dressing, the whole article need not be tested. As a minimum,
portions of 100-500 mg should be cut from that part of the dressing that is most inaccessible to
sterilant. Articles may be pooled.
452.
If the size of an article is such that all its parts are not covered by 2000 mL of medium,
then those parts likely to be most easily accessible to the sterilant may be omitted. Unless the
product is a dressing, before a test is adopted which omits parts of an article from routine
testing, the proposed procedure should be discussed with the competent authority. Parts of an
article should not be omitted from testing in order for articles to be pooled.
453.
Alternatively, a larger vessel containing additional medium
accommodating all parts of the article may be used.
and capable of
454.
Alternatively, if a large article cannot readily be cut into pieces, or only the fluid pathway
of the device is intended to be sterile, medium should be added to the article aseptically and it
should then be sealed and incubated.
455.
If none of the above methods is practicable the article may be rinsed three times with
suitable volumes of medium, so that all surfaces of the article which are required to be sterile
come into intimate contact with medium. The entire washings from each article are then tested
by the method of Membrane Filtration. This method is not as sensitive as those described
above because micro-organisms adhering to surfaces may not be removed by washing. It
should be used only as a last resort.
456.
Care should be taken to ensure that entrapped air does not prevent the medium from
making contact with all parts of the internal surfaces of an article. To facilitate this contact a
surfactant agent is included in Medium 1 and Medium 2; Medium 1 may also be modified by the
omission of agar.
Ointments and oily preparations
457.
Ointments and oily preparations may be tested by the method of Direct Transfer if
testing by the method of Membrane Filtration is not feasible, i.e. when a suitable solvent is not
available (see clauses 429-430).
458.
Before addition to media, ointments and creams may be diluted approximately 1 in 10
by emulsifying with a suitable emulsifying agent in a suitable sterile diluent to improve contact
between the sample and the medium (polysorbate 80 or light liquid paraffin may be useful). In
this case it may be appropriate to use Medium 1 and Medium 2 without polysorbate 80.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 17 of 36
Therapeutic Goods Administration
459.
For oily liquids media containing an emulsifying agent should be used. Polysorbate 80
at 10 g/L, (p-tert-octylphenoxy) polyoxyethanol at 1 g/L, or other emulsifying agents in
appropriate concentration may be suitable.
Initial validation of the test method - testing for antimicrobial activity
460.
The goods to be tested for sterility should be tested for antimicrobial activity during the
product development stages, if this is possible. If they are found to have such activity,
preparatory or test procedures will need to be modified to neutralise this activity.
461.
If goods are found to be free of such activity when first tested, or after modification of
procedures, application of the test for antimicrobial activity to every sample is not necessary.
(See also clauses 405-409).
462
To demonstrate that the mixture does not manifest antimicrobial activity carry out the
test as described above up to the incubation step and add an inoculum of viable cells of the
specified aerobic bacteria, anaerobic bacteria and fungi.
463
To one vessel containing the test sample in Medium 1, add an inoculum of Clostridium
sporogenes ATCC 19404, Staphylococcus aureus ATCC 6538 and Pseudomonas aeruginosa
ATCC 9027 and incubate at 30 – 35°C. To a second vessel containing the test sample in
Medium 2 add an inoculum of Candida albicans ATCC 10231, Bacillus subtilis ATCC 6633 and
Aspergillus niger ATCC 16404 to Medium 2 and incubate the vessel at 20 – 25°C.
464
Other appropriate strains of challenge organisms are listed in Table 5.
465
In each case the number of micro-organisms in the inoculum is to be not more than 100
CFU. (For guidance on preparation of inocula, see Annex I Guidance on Obtaining Small
Numbers of Vegetative Organisms and Spores).
466.
Growth of each of the added micro-organisms should be apparent within 48 hours. If
conspicuous growth does not occur within 5 days, the test procedure is not valid and must be
modified (e.g. by using additional washes, using antagonists to the antimicrobial agent or other
procedure) until conspicuous growth does occur when tests as above are carried out.
467.
Periodically, the strains referred to above should be supplemented by strains of microorganisms collected from the manufacturing environment.
Negative product control tests
468.
The results of negative product control tests facilitate the interpretation of sterility test
results, particularly when used to declare a test invalid because of contamination in the negative
product controls.
469.
During each working session (i.e. that uninterrupted period of time in which a sample or
group of samples is tested) in which sterility testing is carried out, at least ten negative product
control containers should be tested. For a direct inoculation test these controls should be tested
where possible at regular intervals during the test session.
470.
A negative product control is usually a terminally sterilised item of undoubted sterility,
that is, it has been subjected to the equivalent of two sterilisation cycles by autoclaving
or by dry heat sterilisation, or 50 kGy of gamma irradiation. Acceptable alternatives
could be a container that has been aseptically filled and then subjected to 25 kGy or a
container of medium that has been filled during a media fill validation, incubated for 14
days and been found to be sterile.
471.
A negative control should be similar in type and container (or packaging if a device) to
the product under test. The essential element of the negative control is that the manipulations
involved in testing the control should be similar to those involved in testing the product. There
should be similar risks of introducing contamination in the control and product tests.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 18 of 36
Therapeutic Goods Administration
472.
A suitable negative product control for an aqueous product could be distilled water in a
similar container. A negative product control for testing an ointment could be a container of
liquid paraffin or ointment base that has been sterilised by dry heat; pouring the liquid paraffin
from a container would be adequate to simulate squeezing of ointment from a tube. For
disposable devices, a section of glass or plastic tubing packaged in a manner similar to the
device, and sterilised by gamma irradiation, could serve as a negative control.
473.
Where a retest is being carried out in the working session these simulated negative
controls should be processed concurrently with that retest.
474.
The negative control contamination rate should be calculated and recorded. In order to
derive the maximum information from the results of sterility tests it is essential that the level of
contamination detected in negative control tests be minimal.
Incubation and examination of sterility tests
475.
Incubate all test vessels of Medium 1 (or equivalent medium - see clause 402) at 30 35°C. Incubate the vessels of Medium 2 (or equivalent medium - see clause 402) at 20 - 25°C.
476.
All vessels should bear the identity of the product or control being tested, the medium
used, the temperature of incubation and date of inoculation.
477.
All test and control vessels, other than the subcultured vessels referred to below, must
be incubated for at least 14 days unless microbial contamination is detected at an earlier time.
478.
At intervals during the incubation period examine each vessel for evidence of microbial
growth; a suitable interval is 2 working days. Care should be taken to prevent undue agitation of
the Medium 1. At the end of the incubation period examine each vessel again for evidence of
microbial growth after agitating, swirling or inverting the contents.
479.
Preparations that produce a suspension, flocculation or deposit so that the presence or
absence of microbial growth cannot be readily seen should be mixed by gentle swirling or
inversion at each examination until subcultured. Care should be taken to prevent undue
agitation of the Medium 1 and to ensure that anaerobic conditions are maintained as indicated
by the resazurin indicator. After 14 days incubation transfer a suitable portion (not less than 1
mL) of the contents to a fresh vessel of the same medium. Incubate the subcultured vessels for
not less than 4 days at the same temperature as that at which the original vessel was
incubated. Continue incubation of the original and the subcultured vessels for a total of not less
than 14 + 4 days from the original inoculation.
480.
If turbidity, precipitate, or other evidence of microbial growth during incubation is seen:

examine the suspected growth microscopically by Gram stain;

attempt to grow single colonies using appropriate microbiological methods;

examine colonies of each type of micro-organism present for their colonial
morphology and cellular morphology by Gram stain;

attempt to identify the isolates, as far as the genus, and preferably species.
NOTE: If the identity of isolates is to be used as the basis for invalidating a test, a sensitive
method of identification such as molecular typing techniques using RNA/DNA homology
is required (see also clause 495).
481.
Keep records of these cultures in order to detect a pattern of recurring contaminants in
the product. It is recommended that cultures of recurring contaminants be maintained in pure
form and used as reference organisms for evaluation of environmental background
contamination.
482.
Automated or semi-automated biochemical organism identification systems should be
subjected to periodic verification using reference strains of organisms that can be traced to a
recognised reference culture collection, such as the American Type Culture Collection (ATCC),
Maryland, USA, or the National Collection of Type Cultures (NCTC), London, UK.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 19 of 36
Therapeutic Goods Administration
Monitoring the efficacy of test media at the end of the
incubation period (stasis test)
483.
The stasis test is not mandated by the Pharmacopoeias but is recommended as part of
Good Laboratory Practice (GLP) in relation to method validation and a quality system based on
ISO 17025. It is particularly important for antibiotics, slow-release sterile products and for direct
inoculation methods where validity of the test depends on the use of an exact amount of product
(ie, marginal methodology).
484.
The stasis test is intended to demonstrate that the media inoculated with the test
preparation will support growth for the full incubation period. For example, it is necessary to
show that anaerobiosis is maintained in the Medium 1 to allow the late development of slowgrowing anaerobes. It is also necessary to demonstrate that growth promoting qualities of
media are retained and that preservative inhibitors remain stable for the full test period.
485.
The stasis test will be included in referee testing (see clauses 101 and 105).
486
After incubation of the media has been completed in accordance with the instructions
given in clauses 475-479:
 add to representative vessels containing Medium 1 that has been incubated at 30 –
35°C, an inoculum of viable spores of an anaerobic bacterium eg, Clostridium
sporogenes ATCC 19404;
 add to representative vessels containing Medium 2 that has been incubated at 20 –
25°C an inoculum of viable cells of a fungus, eg, Candida albicans ATCC 10231;
NOTE: Acceptable challenge organisms are listed in Table 5. The list is not exclusive; other
micro-organisms may be suitable.
487.
In each case the number of organisms in the inoculum is to be not more than 100 CFU
(see Annex I Guidance on Obtaining Small Numbers of Vegetative Organisms and Spores).
488.
The vessels are returned to their previous temperature and incubation continued. The
containers of product should all show growth of the added organisms within 48 hours. If
conspicuous growth is not apparent within 5 days for both bacteria and fungi the test is
considered invalid. Invalid stasis tests may be repeated once. If conspicuous growth is not
obtained at the second attempt the test method should be modified and revalidated.
489.
If the media are found to support growth of the test micro-organisms then this test need
not be applied to every sample. It should be repeated periodically on the relevant categories of
products or when product is reformulated. Every 12 months is recommended.
490.
Periodically the strains referred to above may be supplemented with appropriate strains
of micro-organisms collected from the manufacturing environment.
Interpretation of the test results
491.
If microbial growth is not evident in any of the vessels inoculated with the product, the
sample tested complies with the test for sterility, provided that growth of challenge organisms
has been demonstrated in the stasis test (if performed), in growth promotion tests on the
batches of media used and in test method validation. This interpretation applies even if growth
occurs in negative product control vessels.
492.
If microbial growth is evident the product does not comply with the test for sterility
unless it can be clearly demonstrated that the test was invalid for causes unrelated to the
product being examined.
493.
If microbial growth is evident, the criteria for invalidating the test are:
(a) the data of the microbiological monitoring of the sterility testing facility show a fault;
(b) a review of the testing procedure used during the test in question reveals a fault;
(c) microbial growth is found in the negative product controls;
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 20 of 36
Therapeutic Goods Administration
(d) after determination of the identity of the micro-organisms isolated from the test, the
growth of this species or these species may be ascribed unequivocally to faults with
respect to the material and/or technique used in conducting the sterility test procedure.
494.
When conditions (a), (b) or (c) apply, the test should be aborted prior to the completion
of the incubation period.
495.
If condition (d) is to be used as the sole criterion for invalidating a sterility test, it is
necessary to employ sensitive typing techniques to demonstrate that a microorganism isolated
from the product test is identical to a microorganism isolated from the materials and/or the
environment. While routine biochemical/phenotypical identification techniques can demonstrate
that two isolates are not identical, these methods are not sufficiently sensitive or reliable enough
to provide unequivocal evidence that two isolates are from the same source. Suitably sensitive
tests (for example, molecular typing with RNA/DNA homology) are those accepted by
microbiologists conducting epidemiological studies to determine that microorganisms are
clonally related and have a common origin.
Repeat testing based on the biochemical or
phenotypical characterisation of environmental and/or product isolates should not be permitted.
The test environment can be contaminated by actual product samples, which may contain
multiple micro-organisms that are difficult to speciate without employing sensitive typing
techniques.
496.
If the test is declared to be invalid it may be repeated with the same number of units as
in the original test.
497.
If there is no evidence of growth in any vessels inoculated with the product during the
repeat test the product passes the test for sterility. This interpretation applies even if growth
occurs in negative product control vessels.
498.
If there is evidence of growth in the test vessels the product fails the test for sterility.
Further testing is not permitted under any circumstances.
499.
If two consecutive tests on the same product give evidence of growth in control vessels,
or consecutive working sessions give evidence of growth in controls, or there is any other
evidence of breakdown in testing methods, then there should be a complete review of all
facilities and testing procedures to determine the cause of the contamination. Further tests on
samples should be suspended until the review is completed.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 21 of 36
Therapeutic Goods Administration
5.
RECORDS
500.
Reference: PIC/S Recommendations on Sterility Testing (PS/W 2/98).
501.
Records should be kept of all sterility testing which is carried out.
502.
For each test these records should contain at least the following information:

description and number of product units tested;

batch/lot number;

stage of manufacture (finished product, intermediate or final bulk);

personnel performing tests;

dates of testing;

test methodology (volume tested, diluents/solvents used, media, media batch
numbers, temperature and time of incubation);

results in full.
503.
Records should also be maintained of:

details of validation of the sterility test method;

periodic stasis testing;

details of any product contamination irrespective of whether the test was valid or
invalid;

the negative control contamination rate;

results of environmental and personnel monitoring.
504.
Results of sterility testing for test samples and negative controls should be presented in
a format that allows for easy recognition of trends.
505.
These records should be appropriately stored and readily available as defined in
Chapter 4 of the Australian Code of Good Manufacturing Practice for Medicinal Products, 2002.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 22 of 36
Therapeutic Goods Administration
6.
MEDIA FOR USE IN STERILITY TESTING
600.
Relevant section of the BP/Ph Eur: ‘Culture Media and Incubation Temperatures’
Composition
601.
Fluid Thioglycollate Medium (Medium 1) and Soybean-Casein Digest Medium (Medium
2) are the media generally used for tests for sterility. The composition of these media should be
as specified in Annex II. Commercially available dried media, which differ slightly from the
specified composition, may be used provided the reconstituted medium has been shown to
support the growth of aerobic and anaerobic bacteria and fungi, as described in clauses 611615.
602.
As noted in clause 402, alternative media types may be appropriate where the nature of
the product or method of manufacture may result in the presence of fastidious organisms (eg,
vaccines, blood products).
603.
Inactivators of antimicrobials may be incorporated into culture media or solutions if
indicated by validation studies.
604.
Media may be either purchased from an approved supplier or manufactured in-house.
Method of preparation
605.
Media should be prepared according to written procedures that are based on a
validated sterilisation process.
606.
Every batch should be assigned a unique batch number and expiry date and its
manufacture documented.
607.
Detailed guidance for preparation of Medium 1 and Medium 2 is provided in Annex II.
Tests on the media
608.
Before use, each batch of the sterilised media should be tested for pH, sterility and
growth promotion.
609.
Measure the pH of a sample of each batch of medium. Any batch of medium of pH not
within the range prescribed in Annex II for that medium should not be used in tests for sterility.
610.
To check for sterility, incubate the media at 30 - 35°C and 20 - 25°C for 14 days. This
testing may be performed on 100% of the batch or on representative portions and may be
conducted concurrently with the product sterility test. Media which contain visible particulate
matter should not be used in tests for sterility. Parametric release of media may be permitted if
media is manufactured under the same conditions and controls as products already approved
by the competent authority for parametric release (see also clause 708).
611.
The ability of media to support the growth of micro-organisms should be tested by
addition of small numbers of challenge organisms (see Annex I Guidance on Obtaining Small
Numbers of Vegetative Organisms and Spores). After each batch of medium has been sterilised
at least two vessels are selected from positions in the steriliser load where the exposure to heat
is likely to be maximal.
612.
Where the medium under examination is Medium 1 add not more than 100 viable
spores/CFU of each of the following species of micro-organisms: Clostridium sporogenes ATCC
19404, Staphylococcus aureus ATCC 6538 and Pseudomonas aeruginosa ATCC 9027.
613.
Where the medium under examination is Medium 2 add not more than 100 viable cells
of Candida albicans ATCC 10231, Bacillus subtilis ATCC 6633 and Aspergillus niger ATCC
16404 to selected vessels.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 23 of 36
Therapeutic Goods Administration
614.
Other appropriate strains of challenge organisms are listed in Table 5. It is
recommended that from time to time the routine strains should be supplemented by using
strains collected from the manufacturing environment.
615.
Growth of the challenge micro-organisms should be apparent within 48 hours. If growth
is not conspicuous in each of the incubated vessels within 3 days in the case of bacteria or 5
days in the case of fungi, the batch should not be used in tests for sterility.
616.
Prepared media purchased from external vendors should be accompanied by
certification of the growth promotion test performed on each batch of media. The test need not
be performed by the sterility testing laboratory provided there is documented control over the
conditions used to transport media between the media manufacturer and the testing laboratory.
Shelf-life
617.
Media may be stored at 2 – 25°C in suitable sealed containers but must not be used
after storage periods that have not been validated. It should be tested for growth promotion
every three months.
618.
Medium 1 of which more than the upper one-half is pink in colour should not be used in
tests for sterility. Vessels of this medium which have become excessively pink may be heated
once only in a steam bath, or in freely flowing steam, until the pink colour disappears.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 24 of 36
Therapeutic Goods Administration
7. DILUENTS, SOLVENTS AND WASH SOLUTIONS
FOR USE IN STERILITY TESTING
700.
Relevant sections of the BP/Ph Eur: ‘Test for sterility of the product to be
examined’; ‘Application of the test to parenteral preparations, ophthalmic and other noninjectable preparations required to comply with the test for sterility’.
Composition
701.
The composition of the diluents referred to in Table 4 (Diluents 1, 2 and 3) are specified
in Annex III.
702.
These diluents may be modified by addition of antimicrobial inactivators or other equally
or more effective diluents may be used, if indicated by validation studies.
Method of preparation
703.
Diluents, solvents and wash solutions should be prepared according to written
procedures that are based on a validated sterilisation process.
704.
Every batch should be assigned a unique batch number and expiry date and its
manufacture documented.
705.
III.
Detailed guidance for preparation of the diluents listed in Table 4 is provided in Annex
Tests on diluents, solvents and wash solutions
706.
Diluents, solvents and wash solutions should be tested before use for pH and where
practicable, for sterility.
707.
Measure the pH of a sample of each batch. Any batch whose pH is not within the range
specified in Annex III for that diluent should not be used in tests for sterility.
708.
To check for sterility, incubate the preparation at 30 - 35°C and 20 - 25°C for 14 days.
This testing may be performed on 100% of the batch or on representative portions and may be
conducted concurrently with the product sterility test. Solutions that are turbid, or which contain
visible particulate matter, should not be used in tests for sterility. Parametric release of diluents
and solvents may be permitted by the competent authority (see also clause 610).
Shelf-life
709.
Diluent 3 which is more than 10 days old should not be used in tests for sterility.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 25 of 36
Therapeutic Goods Administration
ANNEX I. GUIDANCE ON OBTAINING SMALL NUMBERS
OF VEGETATIVE ORGANISMS AND SPORES
All procedures for the preparation, maintenance and cultivation of challenge organisms should
be documented. At the time of use, cultures maintained by seed lot culture techniques should
be no more than 5 passages from the original type culture strain that has been obtained from a
recognised reference culture supplier. The identity (morphological and physiological properties)
should be checked periodically.
The methods described below are for preparing suspensions of low numbers of the challenge
organisms from the major groups (aerobes, anaerobes and fungi) in Table 5. They are provided
as examples of acceptable procedures and are for guidance only. Some incubation times and
temperatures differ from those in the sterility test procedures; they are suggested because they
have been found to provide, for the particular strains used, conditions under which useful
numbers of viable cells can be cultured within 24 hours.
The methods detailed may be modified for other organisms by changing the media, diluents or
culture conditions. Other methodology (such as the use of suspensions on glass beads or
suspensions stored in a 10% glycerol preparation at -70°C) may be equally satisfactory.
Irrespective of the method used, it is advisable for any laboratory to carry out viable counts on
the selected working dilution of each challenge organism on a daily basis for a whole week to
determine the viability (stability) of their particular strains of organisms.
Method for preparation of cell suspension of Staphylococcus aureus or
Pseudomonas aeruginosa
Every 4 months open a new ampoule and subculture to Soy Bean Casein Digest (SCD) broth.
The incubation conditions for these organisms are 24 hours at 37°C for S. aureus and 30°C for
P. aeruginosa. Subculture from the SCD broth to Soy Bean Casein Digest agar (SCDA) slopes
(stock slopes) and concurrently plate on to a SCDA plate to check for purity.
Every month subculture from the stock slope to a fresh SCDA slope.
Every week subculture from the monthly slope to a SCDA plate. If the culture is pure, subculture
from the slope into 10 mL of SCD and incubate for 24 hours at 37°C for S. aureus and 30°C for
P. aeruginosa.
This culture is used to prepare the working dilution as follows:

assuming that the 24 hour culture contains 1 x 109 CFU/mL, carry out sufficient serial
dilutions in 0.1% peptone saline to arrive at approximately 100 CFU/mL;

prepare about 100 mL of this dilution, which will be the working dilution.
Carry out a viable count on the working dilution on SCDA plates.
From the results of the viable count calculate the volume of the working dilution which contains
not more than 100 CFU and use this for validation, growth promotion and stasis testing. A
concurrent viable count should be carried out when performing any of these tests, as a check
that the working dilution has been correctly prepared and calculated.
Store the 100 mL of the working dilution at 2-8°C. Use as needed but do not keep longer than a
week.
Method for Preparation of Cell Suspension of Candida albicans
Every 4 months open a new ampoule and subculture to Sabouraud Dextrose Broth (SDB).
Unless otherwise stated the incubation conditions for this organism are 24-48 hours at 30°C.
Subculture from the SDB to Sabouraud Dextrose Agar (SDA) slopes (stock slopes) and
concurrently plate on to an SDA plate to check for purity. Prepare sufficient stock slopes to last
4 months.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 26 of 36
Therapeutic Goods Administration
Every month subculture from the stock slope to a fresh SDA slope.
Every week subculture from the monthly slope to a SDA plate. If the culture is pure, subculture
from the slope into 10 mL of SCD and incubate for 24 hours at 30°C.
This culture is used to prepare the working dilution, as follows:

assuming that the 24 hour culture contains 1 x 108 CFU/mL, carry out sufficient serial
dilutions in 0.1% peptone saline to arrive at approximately 100 CFU/mL;

prepare about 100 mL of this dilution, which will be the working dilution.
Carry out a viable count on the working dilution on SDA plates and incubate at 30°C for 24
hours.
From the results of the viable count calculate the volume of the working dilution that contains
not more than 100 CFU and use this for validation, growth promotion and stasis testing. A
concurrent viable count should be carried out when performing any of these tests, as a check
that the working dilution has been correctly prepared and calculated.
Store the 100 mL of the working dilution at 2-8°C. Use as needed but do not keep longer than a
week.
Preparation of spore suspensions of Bacillus subtilis
Stock suspension
Preparation of the stock suspension may be carried out every 12 months.
Open ampoule and subculture into SCD and incubate at 37°C for 24 hours.
Inoculate five 45 mL Sporulation Agar slopes (in 100 mL medical flats) with approximately 1.0
mL of the 24 hour broth culture and incubate at 37°C for 5 days. Concurrently, plate the 24 hour
broth culture onto SCDA to check for purity. Incubate at 37°C overnight. Next day, if pure,
discard; otherwise purify.
Check spore production after 5 days by spore stain. If the percentage of cells sporing is less
than 70-80% continue incubation. When a 70-80% spore yield is achieved, wash off the growth
from the flats with 20 mL of sterile normal saline and dispense into sterile McCartney bottles or
centrifuge tubes.
Centrifuge at 1500 rpm for 20 minutes. Decant (and discard) the supernatant liquid.
Resuspend the sediment in 10 mL of fresh sterile normal saline and spin again; repeat this
process three times.
After the third wash decant off the supernatant liquid except for approximately 1mL. Resuspend
the spores in 2 mL of normal saline.
Heat the spore suspension at 56°C for 30 minutes to kill the vegetative cells.
Carry out a viable count on SCDA using peptone saline as diluent, incubating at 37°C for 24
hours. The final preparation should contain approximately 108 spores/mL.
Working dilution suspension
To prepare a working dilution, dilute the spore suspension in peptone saline to contain
approximately 100 spores/mL. Prepare sufficient to last a week for validation, growth promotion
and stasis testing. Keep refrigerated at 2-8°C.
Carry out a viable count on the working dilution on SCDA plates; incubate the plates at 37°C for
24 hours.
From the results of the viable count calculate the volume of the working dilution that contains
not more than 100 CFU and use this for validation, growth promotion and stasis testing. A
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 27 of 36
Therapeutic Goods Administration
concurrent viable count should be carried out when performing any of these tests, as a check
that the working dilution has been correctly prepared and calculated.
Preparation of spore suspension of Clostridium sporogenes
Stock suspension
Preparation of the stock suspension may be carried out every 12 months.
Open ampoule and inoculate into Reinforced Clostridial Medium (RCM). Incubate under
anaerobic conditions at 32°C for 48 hours.
Subculture about 3-5 mL of the broth onto each of five 45 mL solid RCM agar slopes (in 100 mL
medical flats) and incubate anaerobically at 32°C for until 70-80% of the population is sporing
(approximately 2 weeks). Spore production should be checked every few days by spore stain.
When a 70-80% spore yield is achieved, wash off the growth from the flats with 20 mL of sterile
normal saline and dispense into sterile McCartney bottles or centrifuge tubes.
Centrifuge at 1500 rpm for 20 minutes. Decant (and discard) the supernatant liquid.
Resuspend the sediment in 10 mL of fresh sterile normal saline and spin again; repeat this
process three times.
After the third wash decant off the supernatant liquid except for approximately 1mL. Resuspend
the spores in 2 mL of normal saline.
Heat the spore suspension at 56°C for 30 minutes to kill the vegetative cells.
Carry out a viable count on SCDA using peptone saline as diluent, incubating anaerobically at
32-37°C for 24-48 hours. The final preparation should contain approximately 108 spores/mL.
Working dilution suspension
To prepare a working dilution, dilute the spore suspension in peptone saline to contain
approximately 100 spores/mL. Prepare sufficient to last a week for validation, growth promotion
and stasis testing. Keep refrigerated at 2-8°C.
Carry out a viable count on the working dilution on SCDA plates; incubate the plates
anaerobically at 32-37°C for 24-48 hours.
From the results of the viable count calculate the volume of the working dilution that contains
not more than 100 CFU and use this for validation, growth promotion and stasis testing. A
concurrent viable count should be carried out when performing any of these tests, as a check
that the working dilution has been correctly prepared and calculated.
Preparation of spore suspensions of Aspergillus niger
Stock suspension
Preparation of the stock suspension may be carried out every 12 months.
Open ampoule and subculture into SDB and incubate at 25°C for 3 days.
Inoculate five 45 mL SDA slopes (in 100 mL medical flats) with approximately 1.0 mL of the
broth culture and incubate at 25°C for 5 days. Concurrently, plate the broth culture onto SDA to
check for purity. Incubate at 25°C for 3 days. Next day, if pure, discard; otherwise purify.
Check spore production after 5 days by the appearance of black spores on the surface. When
the entire surface of the culture is black, wash off the growth from the flats with 20 mL of sterile
normal saline and dispense into sterile McCartney bottles or centrifuge tubes.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 28 of 36
Therapeutic Goods Administration
Centrifuge at 1500 rpm for 20 minutes. Decant (and discard) the supernatant liquid.
Resuspend the sediment in 10 mL of fresh sterile normal saline and spin again; repeat this
process three times.
After the third wash decant off the supernatant liquid except for approximately 1mL. Resuspend
the spores in 2 mL of normal saline.
Carry out a viable count on SDA using peptone saline as diluent, incubating at 25°C for 3 days.
The final preparation should contain approximately 10 8 spores/mL.
Working dilution suspension
To prepare a working dilution, dilute the spore suspension in peptone saline to contain
approximately 100 spores/mL. Prepare sufficient to last a week for validation, growth promotion
and stasis testing. Keep refrigerated at 2-8°C.
Carry out a viable count on the working dilution on SDA plates; incubate the plates at 25°C for 3
days.
From the results of the viable count calculate the volume of the working dilution that contains
not more than 100 CFU and use this for validation, growth promotion and stasis testing. A
concurrent viable count should be carried out when performing any of these tests, as a check
that the working dilution has been correctly prepared and calculated.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 29 of 36
Therapeutic Goods Administration
ANNEX II. COMPOSITION AND PREPARATION OF
MEDIA
Relevant section of the BP/Ph Eur: ‘Culture media and incubation temperatures’
This Annex describes methods for preparation and sterilisation of the standard sterility test
media (see also Section 6). Commercially available dried media that differ slightly from the
specified composition may be used provided the reconstituted medium has been shown to
support the growth of aerobic and anaerobic bacteria and fungi, as described in clause 611-615.
Alternative media types may be appropriate where the nature of the product or method of
manufacture may result in the presence of fastidious organisms (eg, vaccines, blood products).
Inactivators of antimicrobials may be incorporated into culture media or solutions if indicated by
validation studies.
If heat labile additives such as serum are included the media may be sterilised by a validated
filtration method. Cogent reasons would be required to justify the use of filtration as a method of
sterilisation of media that can be terminally sterilised.
Medium 1 (Fluid Thioglycollate Medium)
Composition
Pancreatic Digest of Casein
Yeast Extract (water-soluble)
Glucose monohydrate/anhydrous
Sodium chloride
L-Cystine
Sodium thioglycollate
0.1% Resazurin Sodium Solution (freshly prepared)
Granulated Agar (moisture not more than 15%)
Purified Water
Polysorbate 80 (optional)
pH after sterilisation (measured at room temperature):
15.0 g
5.0 g
5.5 g/5.0 g
2.5 g
0.5 g
0.5 g
1.0 mL
0.75 g
1000 mL
5.0 mL
7.1± 0.2
Method of preparation
Either
Mix the pancreatic digest of casein, yeast extract, glucose, sodium chloride, L-cystine, agar and
water in the proportions specified above and heat until dissolved. Dissolve the sodium
thioglycollate in the solution. Add the specified quantity of Polysorbate 80 if this ingredient is to
be included. If necessary, add sufficient 1 M sodium hydroxide or 1 M hydrochloric acid so that
after the solution is sterilised its pH will be 7.1± 0.2. If the solution is not clear, heat to boiling but
do not boil, and filter while hot through moistened filter paper. Add the resazurin sodium solution
and mix.
Or
Dissolve a mixture of dehydrated mixture ingredients in the specified proportions, in water.
Observe the instructions provided by the manufacturer of the dehydrated mixture to effect
solution and to obtain a clear solution of the specified pH. Immediately prior to adjusting the pH,
add the specified quantity of Polysorbate 80 if this ingredient is to be included.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 30 of 36
Therapeutic Goods Administration
Medium 2 (Soybean-Casein Digest Medium)
Composition
Pancreatic Digest of Casein
Papain Digest of Soybean Meal
Glucose monohydrate/anhydrous
Sodium chloride
Dipotassium hydrogen phosphate, K2HPO4
Purified Water
Polysorbate 80 (optional)
pH after sterilisation (measured at room temperature):
17.0 g
3.0 g
2.5 g/2.3 g
5.0 g
2.5 g
1000 mL
5.0 mL
7.3±0.2
Method of preparation
Either
Mix the ingredients, in the proportions specified above, warming slightly to effect solution. Cool
the solution to room temperature. Add the specified quantity of Polysorbate 80 if this ingredient
is to be included. If necessary, add sufficient 1 M sodium hydroxide or 1M hydrochloric acid so
that after the solution is sterilised its pH will be 7.3± 0.2. If the solution is not clear filter through
moistened filter paper.
Or
Dissolve a mixture of dehydrated ingredients in water in the amount necessary to obtain the
required concentration. Follow the instructions provided by the manufacturer to obtain a clear
solution of the specified pH. Just prior to adjusting the pH, add the specified quantity of
Polysorbate 80 if this ingredient is to be included.
Both media
Filling and containers
Distribute all media into clear colourless glass vessels with external screw threaded necks in the
required volumes. Each vessel for Medium 1 should provide a ratio of surface to depth of
medium such that when inoculated with a sterile inoculum not more than the upper one-half of
the medium becomes pink in colour at the conclusion of the test for sterility. The capacity of
each vessel for Medium 2 should be at least twice the volume of the medium placed in it. Close
all vessels with aluminium or heat resistant plastic screw-caps.
Sterilisation
Media should be sterilised within four hours of the start of its preparation.
Sterilise the vessels of media by exposing them to saturated steam in an autoclave for a time
sufficient to ensure that the whole of the contents of each vessel is maintained at 121°C for 20
minutes. In the process of sterilisation do not prolong the heating up or delay the cooling down
of the media unnecessarily. Bring the pressure in the autoclave chamber to atmospheric
pressure at such a rate so as not to cause the medium to boil over. Allow the media to cool to
about 30°C, either in the autoclave chamber or a sterile environment, then tighten the cap of
each vessel. Cooling may be carried out in a controlled clean environment provided that the
process has been validated.
Alternative validated terminal sterilisation methods may be used.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 31 of 36
Therapeutic Goods Administration
ANNEX III. COMPOSITION AND PREPARATION OF
DILUENTS
Diluent 1
Composition
Peptic Digest of Animal Tissue
Purified Water
pH after sterilisation (measured at room temperature):
1g
1000 mL
7.1±0.2
Method of preparation
Mix the ingredients in the proportions specified above and heat to dissolve. If necessary, add
sufficient
1 M sodium hydroxide or 1 M hydrochloric acid to bring the pH within the range specified for the
diluent. Distribute into vessels that are closed against the access of micro-organisms, and
sterilise the filled vessels by heating in an autoclave by the method described for sterilisation of
media.
Sterilisation
If necessary, clarify the diluents by filtration, preferably through membrane filters, before
sterilisation. Sterilisation should be performed within four hours of the start of preparation and
should be by exposure of the whole of the contents of each vessel to 121°C for 20 minutes.
Diluent 2
Composition
Peptic Digest of Animal Tissue
Polysorbate 80
Purified Water
pH after sterilisation (measured at room temperature):
1g
1 mL
1000 mL
7.1± 0.2
Method of preparation and sterilisation
Prepare and sterilise as above for Diluent 1.
Diluent 3
Composition
Peptic Digest of Animal Tissue
Disodium hydrogen phosphate, Na2HPO4
Sodium dihydrogen phosphate, NaH2PO4.2H20
Purified Water
Penicillinase solution (15000 Levy Units/mL)
Final pH (measured at room temperature):
1g
8.38 g
1.62 g
1000 mL
100 mL
7.5±0.2
Method of preparation
Proceed as in the preparation of Diluents 1 and 2. After the sterilised solution has cooled to
between 20°C and 30°C, aseptically add the penicillinase.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 32 of 36
Therapeutic Goods Administration
ANNEX IV. STERILITY TEST ENVIRONMENT
This Annex provides guidance for achieving a testing environment that is equivalent to the
conditions required for the aseptic manufacture of pharmaceutical products, as required by the
BP/Ph Eur (section ‘Precautions against microbial contamination’). It incorporates relevant
elements from the Pharmaceutical Inspection Convention/ Pharmaceutical Inspection Cooperation Scheme (PIC/S) Recommendations on Sterility Testing (April 2000), Annex 1 of the
PIC/S Guide to Good Manufacturing Practice for Medicinal Products (August 2001) and the
Australian Code of Good Manufacturing Practice for Medicinal Products Annex 1 – Manufacture
of Sterile Medicinal Products.
Clean-rooms
Classification
Sterility testing should be performed under conditions that meet Class 3.5 of Australian
Standard 1386 or the equivalent European Class A (see Table 6).
The BP/Ph Eur requires that sterility testing is carried out ‘under aseptic conditions’. Guidance is
provided that these conditions can be achieved using, for example, a class A laminar-air-flow
cabinet located within a class B clean-room or an isolator’ (BP/Ph Eur: ‘Precautions Against
Microbial Contamination’).
A Class 3.5 laminar flow cabinet stationed within an AS Class 350 clean-room meets these
criteria. There is no direct equivalent in AS 1386 to a class B environment, however, the counts
accepted for an AS class 350 room are the same as for a class B room ‘in-operation’.
Acceptable alternatives are a Class 3.5 / Class A clean-room or an isolator.
For the testing of potentially dangerous drugs an appropriate laminar flow cabinet with a
protective air curtain or an isolator should be used.
TABLE 6: CLEAN-ROOM ENVIRONMENT CLASSIFICATIONS
Environment
European (PIC/S)
Class
Australian (AS 1386)
number of particles
≥0.5 µm / m3
at rest
in operation
Class
Number of particles
≥0.5 µm / litre
in operation
Laminar flow cabinet;
Isolator
A
3,500
3,500
3.5
3.5
Clean-rooms
B
3,500
350,000
C
350,000
3,500,000
350
350
D
3,500,000
not defined
3,500
3,500
not defined
The testing work zone should provide sufficient space and material should be set out so as not
to disrupt laminar air flow.
Air supply
Air supplied to the environment should be provided through terminal HEPA filters that should be
fitted with audible and/or visual alarms to indicate pressure drop across the HEPA filters. There
should be a pressure differential of 10 to 15 Pascals (guidance value) between each of the
areas, ie, ambient/airlock and airlock/test room. A minimum of 20 air changes per hour is
expected. Prior to operator entry to the test suite, pressure readings should be taken and
recorded from externally mounted gauges labelled to indicate the area served, acceptable
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 33 of 36
Therapeutic Goods Administration
specification and whether or not the reading is absolute or differential. An automated continuous
monitoring system is an acceptable alternative to manual reading.
Certification
The test environment, which includes the laminar flow cabinet or isolator, should be certified at
least annually by a competent person for compliance with the specified conditions.
Airlock
Entry to the clean-room should be via an airlock where operators change into clean-room
garments. The airlock should be designed to facilitate movement of the operator from the
unclean to the clean end of the room without compromising the aseptic gowning procedure. A
step-over bench is a suitable division between these areas. The airlock should contain a fulllength wall mirror, gowning instructions and hand washing/drying facilities.
Clean-room fittings and surfaces
The clean-room should have a minimum of ledges and obstructions to flow of clean air. In
general, fittings such as power outlets and light fittings should be flush with walls/ceiling
surfaces and sealed to prevent the entrainment of unclean air. Surfaces should be smooth and
impervious to the cleaning agents used. The joints between walls/ceilings/floors should be
coved to facilitate cleaning. The intercom or communication system should be designed to allow
hands-free use. Chairs, trolleys and such items should be designed to facilitate cleaning and be
suitable for clean-room use.
There should be no extraneous equipment within the clean-room environment.
Ultraviolet lights may be fitted only in pass-through hatches. If there is more than one parallel
tube they should be shielded from each other. They should be checked at least annually or
whenever new lamps are fitted.
Cleaning, sanitisation and disinfection
There should be written instructions for daily, weekly and periodic cleaning and decontamination
of the test suite. If an isolator is used, the method of disinfection/sterilisation should be
specified. Disinfectants should be free of microbiological contamination, which may be achieved
by aseptic filtration or use of a product-compatible terminal sterilisation method. All disinfectants
and detergents should be monitored by testing for contamination.
All cleaning, sanitising and disinfecting procedures should have been validated for minimum
contact time and efficacy.
Surfaces and operators' gloved hands should be disinfected regularly during the test session.
Environmental monitoring
Environmental monitoring should consist of air sampling, settle plates, surface monitoring and
operators' gloved hand plates. Surfaces can be monitored by contact (RODAC) plates, films or
swabs. The laminar flow area should be monitored as well as the background room area.
Written procedures should specify exposure duration, frequency and location of all monitoring
and include appropriate alert and action limits for microbial contamination. The media used
should be specified and the recovery of micro-organisms from surfaces and on media should be
validated. Suitable disinfectant/cleaning agent inactivators may need to be incorporated in
media.
Records should be maintained of the numbers and types of organisms isolated and results
presented in a format that facilitates early detection of trends. Routine identification of
environmental micro-organisms to at least the genus level should assist in detecting trends. If
the identity of organisms from the environment is to be used as the basis for invalidating a
sterility test and performing a repeat sterility test, then a sensitive method of identification such
as molecular typing techniques using RNA/DNA homology will be expected.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 34 of 36
Therapeutic Goods Administration
Testing Ancillary to the Sterility Test
The exposure and manipulation of cultures increases the likelihood of environmental
contamination. Testing associated with the sterility test but requiring the use of live microorganisms (eg validation, stasis testing) should be carried out in laboratory facilities that are
completely separate from the clean-room. In addition, such aspects of testing for sterility that
necessitate the handling of live cultures should not be carried out in or adjacent to production
areas.
Sterility Testing Operators
Training
Sterility testing should only be performed by personnel who have been trained, qualified and
certified to perform the various tasks and procedures related to sterility testing. The examination
of test and control containers during and at the end of the incubation period should be included
as part of the operator training program. Personnel should undergo periodic re-certification,
particularly when problems are detected during the course of routine environmental and
negative control monitoring, or when operators perform the test infrequently.
The operator's testing technique should be monitored during every test session by use of
negative product controls. Techniques used should be reviewed periodically to ensure that
departures from aseptic practices do not develop. Personnel training should be documented
and records maintained.
Clean-room garments
The sterility test operator should wear sterile clean-room garments that consist of a one-piece
coverall suit, a head cover, a beard cover if applicable, overshoes, gloves and mask. The use of
sanitised garments may be acceptable if the process has been validated and their use is not
used to justify the performance of repeat sterility tests. These garments should be changed for
each work session, or at least once daily if validated by personnel monitoring.
Each operator should be trained and certified in aseptic gowning procedures as part of training
for sterility testing, and training records maintained. Records of sterilisation of garments should
be kept. This may be in the form of a certification from an external supplier of clean-room
garments.
TGA guidelines for sterility testing of therapeutic goods
September 2006
Page 35 of 36
Therapeutic Goods Administration
PO Box 100 Woden ACT 2606 Australia
Email: info@tga.gov.au Phone: 1800 020 653 Fax: 02 6232 8605
www.tga.gov.au